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Abstract
Objective. To evaluate the acceptability and efficacy of medical abortion at home
up to 63 days’ gestation without limits on travel distance to a registered institu-
tion. Design. Observational prospective study. Setting. Haukeland University
Hospital between May 2006 and May 2009. Population. A total of 1018 women
requesting abortion before 63 days’ gestation who chose medical termination
with mifepristone and home administration of misoprostol. Methods. The
women took 200 mg mifepristone under nurse supervision and self-adminis-
tered 800 lg misoprostol vaginally 36–48 h later at home. All were contacted by
phone for follow-up and assessment of bleeding, pain and acceptability. Main
outcome measures. Evacuation rate, pain, bleeding, acceptability, influence of
distance on treatment. Results. Median gestational age was 50 (range 35–
63) days and 70 (7.1%) of the women lived more than 60 min travel from the
clinic. The rate of completed abortion was 93.6% and surgical evacuation was
performed in 50 (4.9%) cases. Two women requested treatment on the day of
misoprostol use. Moderate to strong pain was experienced by 68.4%, and 74.7%
reported moderate to heavy bleeding. Parous women experienced less pain than
nulliparous women (odds ratio 0.27; 95% confidence interval 0.19–0.34). In all,
95.1% of the women were satisfied with staying at home. Travel distance did not
influence treatment outcome variables. Conclusions. In our experience, home
administration of misoprostol is an effective and acceptable method for abortion
up to 63 days of gestation and women should be eligible for this treatment
option regardless of their travel distance from hospital.
Abbreviations: CI, confidence interval; hCG, human chorionic gonadotropin;
OR, odds ratio.
Introduction
Medical abortion with mifepristone and misoprostol is a
well-established and acceptable method (1). It has become
the most common method in Norway since it was intro-
duced in 1998 (2), and was in 80.5% of all medical abor-
tions in 2012 (3). Norway has abortion on request,
completely free of charge and easily accessible at every
gynecology ward up to 12 weeks of gestation (4). The
Key Message
Women find home administration of misoprostol to
be an acceptable method of abortion. As complica-
tions are few and occur several days after the admin-
istration of misoprostol, women should be offered
this method even if they live far from hospital.
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population (5 million) is distributed over a large area,
with many people living in rural areas far from the near-
est hospital. Increasing access to safe and acceptable treat-
ment close to or at home would be an advantage.
Home administration of misoprostol for up to 9 weeks’
gestation has been available in the USA since 2000 (5). In
Europe, on the other hand, except Scandinavia, a more
restrictive attitude towardds home administration of
medical abortion has prevailed. Home administration has
either not been allowed or has been restricted to a lower
gestational age, most commonly up to 49 days (6).
Except for a Swedish study that found home adminis-
tration of misoprostol just as acceptable at 50–63 days’
gestation as at <50 days’ gestation (7), very few studies
from Europe have reported on home treatment beyond
56 days’ gestation. Several studies, including Swedish
studies, have limitations as to the travel time from pro-
vider for those who would like to administer misoprostol
at home (7–9). A 1-h travel limit is not uncommon;
however, none of these studies has looked at the impor-
tance of proximity to provider (7–9). Although the
majority of women in Europe live close to a health facil-
ity, not all women do so, and internationally many
women live in less urbanized settings with limited access
to health facilities.
Medical abortion with home administration of misopr-
ostol up to 63 days’ gestation and no travel distance limi-
tation was introduced at Haukeland University Hospital,
Bergen, Norway, in 2006 with the objective to increase
women’s choice. It rapidly became the preferred proce-
dure for women at this gestational age. Home administra-
tion is here defined as not conducted within the hospital.
The aim of this study was to evaluate the consequences
of implementing home administration of misoprostol.
This method was introduced to increase and facilitate
women’s access to medical abortion regardless of resi-
dence and travel distance from hospital.
Material and methods
This observational study involved women (n = 1018)
requesting medical abortion (4) at the Department of
Obstetrics and Gynecology, Haukeland University Hospi-
tal, Bergen. All women who requested abortion between
May 2006 and May 2009 with a documented pregnancy
length of up to 63 days’ gestation were eligible. Excep-
tions were age below 18 years or lacking the ability to
understand and fulfill the treatment. No limits to travel
time from home to the Hospital were made. Oral and
written information about the method was given. The
women chose by informed consent to undergo a medical
termination with mifepristone intake under nurse super-
vision and self-administration of misoprostol at home,
rather than under supervision by health professionals at
the Hospital.
Since the objective of introducing home administration
was to minimize the number of visits, only one consulta-
tion at the out-patient clinic was planned. The gestational
age was established by a vaginal ultrasound which mea-
sured the crown–rump length with 23 mm as an upper
limit (10) or a gestational sac with a present yolk sac. All
women requesting abortion were screened for Chlamydia
trachomatis and all received advice on post-abortion con-
traception use. Women were not screened for bacterial
vaginosis and none received prophylactic antibiotics.
After counseling, women who chose home administra-
tion of misoprostol subsequently took mifepristone
200 mg orally under nurse supervision. According to
Norwegian law, abortions should take place in hospitals.
Administration of mifepristone in hospitals is defined to
be in accordance with the law. All women were instructed
to insert 800 lg misoprostol vaginally themselves 36–48 h
later followed by 50 mg diclofenac and 600 mg paraceta-
mol with 30 mg codeinsulfate orally as analgesics. Written
information together with carefully labeled packets con-
taining 800 lg misoprostol, diclofenac and paracetamol
with codeine sulfate was given out together with a contact
phone number for any questions and concerns. All
women were advised to have an accompanying person
with them on the day of misoprostol administration and
all received a phone call from a trained nurse the day of
misoprostol use, to follow up their treatment and wellbe-
ing. During the conversation they were asked to self-
assess the level of bleeding as none, light, moderate or
heavy, and pain as none, light, moderate or strong. Addi-
tionally, they were questioned about the acceptability
through the questions: (i) Would you rather have been at
the hospital? and (ii) Are you content with being at
home?
According to standard control at our Hospital, all
women were instructed to take a blood test on the day of
mifepristone intake and after 4 weeks to measure serum
human chorionic gonadotropin (hCG) to confirm that
they were no longer pregnant (11). The blood test could
be taken at their local medical health center but all results
were sent to our clinic for evaluation. Women who failed
to have this follow-up blood test were contacted by
phone two times and given a reminder. A systematic
search through hospital files was done for all women to
look for unscheduled visits and complications. Supple-
mentary misoprostol, admission to hospital, infection and
surgery were considered additional treatment. The num-
ber of days from administration of mifepristone until a
complication occurred was also registered.
Travel time by car was measured using the web page
“Visveg” (http://visveg.vegvesen.no/Visveg/mapviewer.jsf?
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width=1280&height=512) of the Norwegian Public Roads
Administration that calculates travel distance and time
between two given addresses.
Serum hCG was measured with a commercial two-site
chemiluminescent immunometric assay kit (Immulite
2000 HCG; Siemens Medical Solutions Diagnostics, Los
Angeles, CA, USA). The assay has a detection limit of
3 U/L.
The Committee for Medical and Health Research Eth-
ics, Western Norway, approved the study (number 2009/
738) and found that according to Norwegian law a writ-
ten consent form from each of the women was not
needed. This is an observational, quality control study of
an established procedure where the women themselves
chose between home-based and hospital-based treatment.
Guidelines for experimental clinical trials requiring indi-
vidual written consent were found not to apply for this
study approach.
Statistical analysis
To measure statistical significance and explore associa-
tions between given variables, odds ratios (ORs) were cal-
culated by logistic regression. The mean number of
terminations with home administration of misoprostol
per month per year for the whole study period was used
to illustrate the increased use of the method. Statistical
analyses were carried out using the Statistical Package
for Social Sciences for Windows, release 18 (SPSS Inc.,
Chicago, IL, USA).
Results
During the implementation period, 1018 women with
gestational age of up to 63 days chose medical abortion
with mifepristone and home administration of misopros-
tol as an alternative to staying in hospital during the
expulsion of their pregnancy. Gestational age was deter-
mined by vaginal ultrasound in all women but informa-
tion about the actual crown–rump length was not
recorded for two women. In total, 70 (7.1%, 95% CI 5.5–
8.7%) of the women lived more than 60 min travel by
car away from the hospital. Characteristics of the women
are given in Table 1. The number of women requesting
abortion at this gestational age and the percentage of
medical abortions remained stable during the study per-
iod. There was an increase in the use of the method
among women who were eligible for the treatment alter-
native. By the end of the period, approximately 70% of
all eligible women chose home administration of misopr-
ostol. All women in the study inserted misoprostol them-
selves at home.
In all, 766 women completed the serum hCG blood
test (75.2%, 95% CI 72.6–77.9%). Through hospital files
or phone consultations, follow-up information on a fur-
ther 204 (20.0%) women was obtained. A remaining 48
women were lost to follow up (4.7%).
The complete termination rate with no unplanned vis-
its was 953/1018, 93.6% (95% CI 92.1–95.1%). Informa-
tion about all additional contacts is shown in Table S1.
Three women had a failed treatment with an ongoing,
viable pregnancy (0.3%, CI 0.04–0.6%). None of them
lived further than 60 min travel away from hospital. Two
of these women had a gestational age of between 56 and
63 days when the procedure was started. One woman was
15 weeks pregnant when the ongoing pregnancy was
detected. She fulfilled the treatment medically according
to our clinic’s second trimester procedure (12). The
remaining two pregnancies were terminated surgically.
A total of 50 women underwent surgical intervention.
Median gestational age for those who underwent surgery
was 50 days (range 35–62 days). Women with a gesta-
tional age of 56–63 days had a higher risk of requiring
surgery (OR 2.06; 95% CI 1.08–3.92) compared with the
Table 1. Characteristics of 1018 women undergoing medical abortion through self-administered vaginal misoprostol at home, by gestational
age.
Gestational age
>60 min travel<49 days 49–55 days 56–63 days All
n (%) 436 (42.8) 310 (30.5) 270 (26.5) 1018 (100.0) 70
Age in days, median (range) 27 (18–48) 27 (18–44) 28 (18–46) 27 (18–48) 29 (18–43)
Previous births, median (range) 0 (0–9) 1 (0–7) 1 (0–4) 0 (0–9) 1 (0–6)
Nulliparous, n (%) 393 (90.1) 145 (46.8) 115 (42.6) 653 (64,1) 23 (32.9)
Prior abortions median (range) 0 (0–3) 0 (0–4) 0 (0–4) 0 (0–4) 0 (0–3)
No prior abortion, n (%) 265 (60.8) 189 (61.0) 169 (62.6) 623 (61.2) 42 (60.0)
Travel time to provider in minutes: median (range) 15 (1–540) 16 (1–215) 15.5 (1–416) 15 (1–540) 113 (62–540)
>60 min, n (%) 28/419 (6.7) 22/305 (7.2) 20/264 (7.6) 70/988 (7.1)
Lost to follow up, n (%) 21 (4.8) 15 (4.8) 12 (4.4) 48 (4.7) 6 (8.6)
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gestational age group of <49 days. There was no differ-
ence between gestational age groups 49–55 days and
<49 days (OR 0.78; 95% CI 0.35–1.70). Prolonged bleed-
ing was the most common reason for surgery (32/50,
64%, CI 50.7–77.3%) (Table 2). In this group the median
number of days from intake of mifepristone to surgical
vacuum aspiration was 42 (range 8–107) (Table S1). Six
of the aspirations were performed <30 days after mifepri-
stone intake. One woman (0.1%, CI 0.09–0.3%) needed
blood transfusion. Her hemoglobin was 6.4 g/dL. She
lived 12 min from hospital and contact the hospital due
to profuse bleeding 3 weeks post-abortion. Four (8.0%,
CI 0.5–15.5%) women had a surgical vacuum aspiration
due to abundant bleeding. One of these aspirations was
undertaken on the day of misoprostol use (Table S1).
Twelve had surgery for suspected infections (1.2%, CI
0.5–1.8%) (Table S1). We found no correlation between
endometrial thickness and the need for surgical interven-
tion (Table S1).
In all, 980 (93.3%, CI 95.1–97.4%) women reported
on their level of vaginal bleeding (Table 3). There was a
marginally significant increase in the rate of heavy bleed-
ing in the higher gestational age groups, 49–55 days vs.
<49 days (OR 1.43; 95% CI 1.06–1.93) and the gesta-
tional age group 56–63 days compared with <49 days
(OR 1.59; 95% CI 1.16–2.17). Among the 983 women
(96.6%, CI 95.4–97.7%) who reported their level of pain
(Table 3) we found that parous women experienced less
pain than did nulliparous women (OR 0.27; 95% CI
0.19–0.38) (Figure 1). No difference was found in the
level of pain between the three gestational age groups
when this was adjusted for parity; 49–55 days compared
with <49 days (OR 1.47; 95% CI 0.94–2.29) and 56–
63 days compared with <49 days (OR 1.44; 95% CI
0.89–2.33).
The acceptability of the procedure is illustrated in
Table 4. A total of 95.8% (CI 94.5–97.1%) were more
content staying at home than in the hospital. There was
no difference in the likelihood that women living more
than 60 min travel away would prefer hospital (OR 0.33;
95% CI 0.05–2.4) compared with women living within
60 min of the hospital. Women living more than 60 min
Table 2. Indications for surgery (n = 50; 4.9%).
Gestational age <49 days (n = 436) 49–55 days (n = 310) 56–63 days (n = 270) Total (n = 1018)
Indications for surgery, n (%) 18/436 (4.1%) 10/310 (3.2%) 22/270 (8.1%) 50/1018 (4.9%)
Continuing pregnancy 0 0 2 2 (4%)
Incomplete abortion 0 1 2 3 (6%)
Infection 1 3 5 9 (18%)
Profuse bleeding 1 0 3 4 (8%)
Prolonged bleeding 16 6 10 32 (64%)
Table 3. Incomplete abortions, pain, bleeding and surgical evacuation at different gestational ages. Pain and bleeding is evaluated by the
women themselves at the day of misoprostol use.
Gestational age
<49 days 49–55 days 56–63 days All
n (%) 436 (42.8) 310 (30.5) 270 (26.5) 1018 (100)a
Pain n = 421 n = 300 n = 259 n = 983
None, n (%) 23 (5.5) 10 (3.3) 8 (3.1) 41 (4.2)
Light, n (%) 123 (29.2) 83 (27.7) 63 (24.3) 270 (27.5)
Moderate, n (%) 165 (39.2) 102 (34.0) 103 (39.8) 372 (37.8)
Strong, n (%) 110 (26.1) 105 (35.0) 85 (32.8) 300 (30.5)
Bleeding n = 422 n = 300 n = 255 n = 977
None, n (%) 11 (2.6) 10 (3.3) 7 (2.7) 28 (2.9)
Light, n (%) 71 (16.8) 27 (9.0) 36 (14.1) 134 (13.7)
Moderate, n (%) 170 (40.3) 116 (38.7) 80 (31.4) 366 (37.5)
Heavy, n (%) 149 (35.3) 114 (38.0) 103 (40.4) 366 (37.5)
Very heavy, n (%) 21 (5.0) 33 (11.0) 29 (11.4) 83 (8.5)
Surgical evacuation, n (%) 18/435 (4.1) 10/310 (3.2) 22/270 (8.1)b 50/1018 (4.9)
Logistic regression analyses were made comparing the gestational age groups for all variables. No difference was found when corrected for parity
and age except in the case of surgical evacuation.
aTwo women were registered as <9 weeks but without further specifications.
bIn comparison with gestational age <7 weeks (OR 2.06; 95% CI 1.08–3.93).
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from hospital did not differ from women living closer
than 61 min away in their level of pain (OR 0.6; 95% CI
0.3–1.7), bleeding (OR 1.2; 95% CI 0.7–2.0) or need of
surgery (OR 0.8; 95% CI 0.2–2.7).
Discussion
This study of 1018 women undergoing abortion with
home administration of misoprostol up to 63 days’ gesta-
tion represents the first report where the importance of
proximity to the responsible institution has been exam-
ined. The protocol used was found to be effective and
highly acceptable regardless of women’s travel time to the
clinic. Only two women experienced complications that
needed medical intervention within the first 24 h after
misoprostol application. In the course of the study per-
iod, the method became the preferred procedure for
women at this gestational age in our region.
The rate of surgical intervention (4.9%) in our study is
in line with that in other studies (2,7,13) and the World
Health Organization goal/standard (14). Similar to find-
ings in the World Health Organization study (15), we
identified a statistically significant higher percentage of
women in the group 56–63 days who needed a surgical
aspiration (8.1%) compared with the two other gesta-
tional age groups (4.1% and 3.2%) (Table 3). This might
indicate a need for a modified treatment protocol with
additional misoprostol at this gestational age more similar
to what is used for late 1st trimester abortions, where
additional doses of 400 lg misoprostol is given (16).
Even though the evacuation rate is higher between 56 and
63 days’ gestation, the success rate is still acceptable at
this gestational age. The decision to intervene surgically
was related to the experience of the doctors on call, as no
objective criteria were predetermined. As previously
reported in other studies, we found no correlation between
endometrial thickness and the need for surgical interven-
tion (17). The medical indication for some of the aspira-
tions is not clear in the medical records, or they are missing
because the procedure was undertaken at a different insti-
tution. Retrospectively, some of the aspirations could have
been avoided, which in turn would have improved the suc-
cess rate. The considerable difference in the number of
aspirations found in studies on medical abortion (13,18,19)
shows that further studies into post-abortion treatment
and indications for surgery would be useful.
Since many studies impose limitations on the travel
time from provider for those who wish to administer mi-
soprostol at home (7–9,18) it is interesting to note that
almost all interventions took place more than 24 h after
misoprostol application. Only one woman in the exam-
ined cohort needed a vacuum aspiration on the actual
Figure 1. Self-reported pain vs. parity. Parous women have less
likelihood of experiencing strong pain than nulliparous women
(n = 983; OR 0.27; 95% CI 0.19–0.34).
Table 4. Acceptability of treatment at different gestational ages and more than 60 min travel to provider.








n = 414 n = 293 n = 255 n = 962 n = 65 n = 875
Yes, n (%) 13 (3.1) 12 (4.1) 17 (6.7) 42 (4.4) 1 (1.5) 39 (4.5)




n = 409 n = 290 n = 252 n = 953 n = 65 n = 864
Yes, n (%) 398 (97.3) 275 (94.8) 238 (94.4) 913 (95.8) 65 (100) 826 (95.6)
No, n (%) 11 (2.7) 15 (5.2) 14 (5.6) 40 (4.2) 0 (0) 38 (4.4)
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day of the abortion; the majority made contact more than
1 week after the initial intake of mifepristone. No studies
limit women’s access to medical abortion due to their
travel distance from provider if the abortion is terminated
while present in a clinic. Complications are just as likely
to happen at the same time in the course of the treatment
after discharge from the clinic as when the misoprostol
protocol is administered at home.
Our present study confirms that nulliparous women
experience more pain than women who have given birth
(20,21). Other studies have suggested that the level of
pain also increases with gestational age (1,20). When
adjusted for parity we could not confirm this.
In spite of numerous phone calls to try to contact the
non-compliant women, 4.7% were lost to follow up.
Haukeland University Hospital is the main provider of
abortion in the region (approximately 95%) and it is
rare for women to seek help at a different institution.
Studies have shown previously that women are accurate
at predicting the expulsion of the pregnancy during a
medical termination (22,23). A reason for these women
not to follow the control regimen could be that they
were sure that they had expelled the fetus and did not
feel the need for a control. On the other hand, we can-
not be sure that these women did not seek treatment
elsewhere.
The acceptance rate in our study is similar to what has
been described by others and us earlier (5,7). The fraction
of women choosing home administration of misoprostol
for early first trimester abortions has more than doubled
during the study period. We believe the increased use
may be due to word of mouth and women sharing their
experiences with this treatment alternative as an accept-
able and favorable alternative.
All women were asked if they would rather have been
in hospital or if they preferred being at home. At the time
contact was made, some of the women may not yet have
entered the more painful phase of the process. This could
have resulted in a higher rate of acceptability. We chose
to ask them at the time they were having the termination
because it was the actual time they would have been in
hospital if they had not chosen to be at home. The vast
majority said that they preferred staying at home. The
acceptance rate was, interestingly though not statistically
significant, higher among those living more than 60 min
away from the hospital.
Home administration reduces the number of visits to
hospital, making this method particularly advantageous
for women who live more than 1 h away. A study of
medical abortion prescribed through telemedicine (24)
has shown this to be acceptable and efficient. There were
no differences in our study for any of the parameters
regardless of travel distance to the clinic. Only a very
limited number of women in our study lived further
away than 1 h’s travel, which limits the strength of the
findings based on the travel distance parameters. On the
other hand, we allow women to have a medical abortion
in hospital regardless of their travel distance. In our
study the complications occurred several days after
intake of misoprostol. This suggests that travel distance
restrictions are of minor importance in preventing
adverse events. In comparison, the women in our study
would also have had to travel the same distance for
advanced pregnancies and deliveries. Knowing that medi-
cal abortion is a safer procedure than childbirth (25)
there should be no medical reasons preventing the
women living a greater distance from hospital from hav-
ing the same possibilities and choices as women living
closer to hospital.
In conclusion, according to our experience home admin-
istration of misoprostol is an effective and acceptable
method for abortion up to 63 days’ gestation. Over the
course of the study period, home use of misoprostol has
become the most commonly used method for abortion up
to 63 days’ gestation in our region. With only two women
needing medical assistance on the day of misoprostol use
and in light of previous knowledge (1) there should be no
reason to impose other restrictions on women taking mi-
soprostol at home than at the clinic. Women should be
offered this treatment option regardless of where they live.
We recommend similar studies in other settings to explore
the generalizability of our findings.
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